Henry Schein, Inc. (NASDAQ:HSIC) Given Consensus Recommendation of “Hold” by Brokerages

Henry Schein, Inc. (NASDAQ:HSIC) has received a consensus recommendation of “Hold” from the fourteen brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $86.8333.

Several research analysts recently commented on HSIC shares. Mizuho reduced their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Leerink Partners reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. JPMorgan Chase & Co. raised their target price on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Robert W. Baird set a $97.00 target price on Henry Schein in a research report on Wednesday, May 6th.

Insider Activity at Henry Schein

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the completion of the transaction, the director directly owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas C. Popeck sold 1,355 shares of Henry Schein stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the transaction, the chief executive officer directly owned 86,182 shares of the company’s stock, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 12,968 shares of company stock valued at $1,030,477. Insiders own 0.89% of the company’s stock.

Institutional Trading of Henry Schein

Hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in shares of Henry Schein by 47.3% in the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after purchasing an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after acquiring an additional 229 shares during the period. Acadian Asset Management LLC bought a new stake in Henry Schein in the 1st quarter valued at $676,000. Cetera Investment Advisers raised its stake in Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock valued at $406,000 after acquiring an additional 637 shares during the period. Finally, First Trust Advisors LP raised its stake in Henry Schein by 0.8% in the 2nd quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock valued at $16,154,000 after acquiring an additional 1,669 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Trading Down 0.2%

Shares of Henry Schein stock opened at $76.40 on Tuesday. The company’s fifty day simple moving average is $74.49 and its 200-day simple moving average is $75.85. The company has a market cap of $8.70 billion, a price-to-earnings ratio of 23.08, a PEG ratio of 1.92 and a beta of 0.82. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. Henry Schein has a 1 year low of $61.94 and a 1 year high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. Henry Schein’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts expect that Henry Schein will post 5.32 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.